Advanced search
Publication Cover
Journal of Medical Economics Volume 22, 2019 - Issue 1
Submit an article Journal homepage
1,413
Views
12
CrossRef citations to date
0
Altmetric
Neurology

Cost-effectiveness of alemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison

Saeed TaheriDepartment of Pharmacoeconomics and Pharma Management, School of Pharmacy, Shahid Beheshti University of Medical Science, Tehran, Iran; ORCID Iconhttp://orcid.org/0000-0003-0614-8762
ORCID Icon,
Mohammad Ali SahraianMS Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, IranORCID Iconhttp://orcid.org/0000-0002-3224-8807
ORCID Icon &
Nazila YousefiDepartment of Pharmacoeconomics and Pharma Management, School of Pharmacy, Shahid Beheshti University of Medical Science, Tehran, Iran; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-8079-7424
ORCID Icon
Pages 71-84 | Received 18 Aug 2018, Accepted 21 Oct 2018, Published online: 20 Nov 2018

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Umakanth Vudumula, Mausam Patidar, Kapil Gudala, Elizabeth Karpf & Nicholas Adlard. (2023) Evaluating the impact of early vs delayed ofatumumab initiation and estimating the long-term outcomes of ofatumumab vs teriflunomide in relapsing multiple sclerosis patients in Spain. Journal of Medical Economics 26:1, pages 11-18.
Read now
Behzad Fatemi, Soheila Rezaei, Saeed Taheri & Farzad Peiravian. (2021) Cost-effectiveness analysis of tofacitinib compared with adalimumab and etanercept in the treatment of severe active rheumatoid arthritis; Iranian experience. Expert Review of Pharmacoeconomics & Outcomes Research 21:4, pages 775-784.
Read now
Surachat Ngorsuraches & Nabin Poudel. (2021) Incorporating patients’ preferences in the value assessment of disease-modifying therapies for multiple sclerosis: a narrative review. Expert Review of Pharmacoeconomics & Outcomes Research 21:2, pages 183-195.
Read now

Articles from other publishers (9)

B. Rodríguez-Sánchez, S. Daugbjerg, L. M. Peña-Longobardo, J. Oliva-Moreno, I. Aranda-Reneo, A. Cicchetti & J. López-Bastida. (2022) Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease. The European Journal of Health Economics 24:2, pages 247-277.
Crossref
Y. Seitaridou, M. Dimitrova, T. Chamova, M. Kamusheva & P. Panayotov. (2022) Cost-Effectiveness of Multiple Sclerosis Therapies – A Literature Review. Acta Medica Bulgarica 49:4, pages 69-80.
Crossref
Mouaddh Abdulmalik Nagi, Pramitha Esha Nirmala Dewi, Montarat Thavorncharoensap & Sermsiri Sangroongruangsri. (2021) A Systematic Review on Economic Evaluation Studies of Diagnostic and Therapeutic Interventions in the Middle East and North Africa. Applied Health Economics and Health Policy 20:3, pages 315-335.
Crossref
Mehdi Rezaee, Mohammad Hossein Morowvat, Maryam Poursadeghfard, Armin Radgoudarzi & Khosro Keshavarz. (2022) Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis. BMC Health Services Research 22:1.
Crossref
Anggie Wiyani, Lohit Badgujar, Vivek Khurana & Nicholas Adlard. (2021) How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review. Neurology and Therapy 10:2, pages 557-583.
Crossref
S. Simeonova & R. Nikolova. (2021) Significance of the Dominant Psychological and Physiological Aspects of the Occupational Stress Models. Acta Medica Bulgarica 48:4, pages 33-42.
Crossref
Reza Hashempour, Behzad Raei, Majid Safaei Lari, Nasrin Abolhasanbeigi Gallezan & Ali AkbariSari. (2021) QALY league table of Iran: a practical method for better resource allocation. Cost Effectiveness and Resource Allocation 19:1.
Crossref
Andrew J Palmer, Ingrid van der Mei, Bruce V Taylor, Philip M Clarke, Steve SimpsonJrJr & Hasnat Ahmad. (2019) Modelling the impact of multiple sclerosis on life expectancy, quality-adjusted life years and total lifetime costs: Evidence from Australia. Multiple Sclerosis Journal 26:4, pages 411-420.
Crossref
Lisa Batcheller & David Baker. (2019) Cost of disease modifying therapies for multiple sclerosis: Is front-loading the answer?. Journal of the Neurological Sciences 404, pages 19-28.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.